First Wave BioPharma is a clinical stage biopharmaceutical company based in Brooklyn, NY, specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Their product portfolio includes capeserod, a selective 5-HT4 receptor partial agonist, adrulipase, a recombinant lipase enzyme, and niclosamide, an oral small molecule with anti-inflammatory properties.
With a focus on GI-disease programs, First Wave BioPharma aims to address various clinical indications, ranging from nutritional disorders to diseases caused by immune malfunction. Their targets include patient populations with digestive disorders, such as exocrine pancreatic insufficiency and inflammatory bowel diseases like ulcerative colitis and Crohn's disease.
Generated from the website